The drugmaker has more than ₹500 crore of capital available and is evaluating businesses that can add differentiated chemistry, regulatory access and export capabilities
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.